ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 7, 2019--
LifeMap Sciences (“LifeMap”),
a subsidiary of
AgeX
Therapeutics
, Inc. (NYSE American: AGE), announced today that it has
entered into a collaboration with iCarbonX
Research Shenzhen, enabling iCarbonX to leverage LifeMap’s GeneCards®
Suite platform in product prototype design and scientific research.
LifeMap Sciences is a leading biomedical knowledgebase company that
commercializes the popular GeneCards Suite, including GeneCards®,
the Human Gene Compendium, MalaCards®,
the Human Disease Database, as well as sophisticated analytic tools
based on the comprehensive suite. LifeMap’s user base includes more than
four million researchers world-wide and its customers include top-tier
pharma and biotech customers. The GeneCards Suite has been developed in
collaboration with the Weizmann Institute of Science in Israel.
LifeMap Sciences has recently started offering access to its integrated
knowledgebase and analytic tools via specialized application program
interfaces or APIs for aims spanning drug discovery and repurposing,
point of care solutions, next generation sequencing interpretation,
internal bioinformatics platforms and enrichment of precision medicine
solutions. These APIs enable companies like iCarbonX to integrate
knowledge from the GeneCards Suite Knowledgebase into their existing
processes and research pipelines.
“LifeMap offers sophisticated tools for integrated analysis and big
data-driven biological informatic associations,” said Hancheng Zheng,
the Director of Bioinformatics and AI Platform at iCarbonX. “Its
GeneCards Suite significantly improves the efficacy of scientific
researchers and life science professionals, and it has been helpful to
us in product prototype design and scientific research.”
“LifeMap’s integrated knowledgebase enables organizations to
economically and rapidly acquire and implement integrated biomedical
data solutions into their existing platform,” commented Yaron Guan
Golan, CEO of LifeMap Sciences. “iCarbonX is one of our most
sophisticated users in this area, and is using machine learning and big
data analysis solutions aimed at improving health and well-being. As a
leader in its field, we are proud to be part of iCarbonX’s partner
network and to empower their research with our knowledgebase data and
solutions.”
For inquiries regarding the use of GeneCards Knowledgebase Suite data
and tools, contact Yaron Guan Golan, CEO at LifeMap Sciences: yg@lifemapsc.com.
About LifeMap Sciences
LifeMap Sciences is a life sciences technology company that offers
integrated, streamlined solutions empowering life scientists worldwide
in conducting cutting-edge basic, clinical and applied biomedical
research. LifeMap’s products are used in more than 3,000 institutions
including academia, research hospitals, patent offices, and leading
biopharma and diagnostic companies. Operations worldwide are carried out
from our offices in California, Massachusetts, New Jersey, Tel Aviv, and
Hong Kong.
For more information, please visit https://www.lifemapsc.com
About iCarbonX
Digital health pioneer iCarbonX is creating the new global standard for
health, wellness and healthcare by building the platform for digitizing,
analyzing, and understanding life. With breakthrough technologies, deep
multi-omics, artificial intelligence and experiential data, it delivers
products, services and solutions for both partners and consumers to help
people optimize their lives, from wellness, skincare and fitness, to
health, nutrition and prevention, to health care, condition management
and outcome achievement.
For more information, please visit http://www.icarbonx.com
About the Weizmann Institute of Science and GeneCards
The Weizmann Institute of Science in Rehovot, Israel, is one of the
world’s top-ranking multidisciplinary research institutions. Noted for
its wide-ranging exploration of the natural and exact sciences, the
Institute is home to scientists, postdoctoral fellows, Ph.D. and M.Sc.
students, and scientific, technical and administrative staff. In
addition, visiting scientists and their families – over 500 from 35
countries are regularly hosted at the Institute. Particular excellence
in bioinformatics and systems biology is manifested, among others, in
the GeneCards project, initiated in 1996, under the leadership of Prof.
Doron Lancet of the Dept. of Molecular Genetics, until recently Head of
the Crown Human Genome Center. The team, led by Marilyn Safran,
continuously innovates to maintain GeneCards as the leading integrated
human gene compendium. GeneCards® is a registered trademark
of Yeda Research and Development Co. Ltd.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing
and commercializing innovative therapeutics for human aging. Its PureStem® and
UniverCyte™ manufacturing and immunotolerance technologies
are designed to work together to generate highly defined, universal,
allogeneic, off-the-shelf pluripotent stem cell-derived young cells of
any type for application in a whole host of diseases with a high unmet
medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat
cells) for Type II diabetes. AgeX’s revolutionary longevity platform
named induced Tissue Regeneration (iTR™) aims to unlock cellular
immortality and regenerative capacity to reverse age-related changes
within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical
development. HyStem® is AgeX’s delivery technology to stably
engraft PureStem cell therapies and slowly release iTR molecules in the
body. AgeX is aggressively developing its core product pipeline for use
in the clinic to extend human healthspan, and is seeking opportunities
to form licensing and partnership agreements around its broad IP estate
and proprietary technology platforms for non-core clinical applications.
For more information, please visit www.agexinc.com
or connect with the company on Twitter,
Facebook
and
YouTube
.
Forward-Looking Statements
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not historical fact
including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the business of AgeX Therapeutics, Inc. and
its subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of AgeX’s
Information Statement filed as an exhibit to its Registration Statement
on Form 10 with the Securities and Exchange Commissions (copies of which
may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005245/en/
Source: AgeX Therapeutics, Inc.
Media Contact for AgeX:
Bill
Douglass
Gotham
Communications, LLC
bill@gothamcomm.com
(646)
504-0890